Resveratrol Ameliorates Arterial Stiffness Assessed by Cardio-Ankle Vascular Index in Patients With Type 2 Diabetes Mellitus

• Published in: International Heart Journal Vol. 58; no. 4; pp. 577 - 583
• Main Authors: Imamura, Haruki, Yamaguchi, Takashi, Nagayama, Daiji, Saiki, Atsuhito, Shirai, Kohji, Tatsuno, Ichiro
• Format: Journal Article
• Language: English
• Published: Japan International Heart Journal Association 01.01.2017; Japan Science and Technology Agency
• Subjects: Administration, Oral; Ankle; Ankle Brachial Index; Antioxidants; Arteriosclerosis; Atherosclerosis; Atherosclerosis - complications; Atherosclerosis - drug therapy; Atherosclerosis - physiopathology; Blood pressure; Body mass index; Body weight; Clinical trials; d-ROMs; Diabetes; Diabetes mellitus; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - physiopathology; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Metabolites; Middle Aged; Oxidative stress; Oxidative Stress - drug effects; Polyphenol; Resveratrol; Retrospective Studies; Stilbenes - administration & dosage; Supplements; Treatment Outcome; Vascular function; Vascular Stiffness - drug effects; Weight loss; Oxidative stress; Polyphenol; Body weight; Atherosclerosis; Weight loss; d-ROMs; Vascular function
• ISSN: 1349-2365; 1349-3299
• DOI: 10.1536/ihj.16-373

Resveratrol has been reported to have potent anti-atherosclerotic effects in animal studies. However, there are few interventional studies in human patients with atherosclerogenic diseases. The cardio-ankle vascular index (CAVI) reflects arterial stiffness and is a clinical surrogate marker of atherosclerosis. The aim of the present study was to investigate the effect of resveratrol on arterial stiffness assessed by CAVI in patients with type 2 diabetes mellitus (T2DM).In this double-blind, randomized, placebo-controlled study, 50 patients with T2DM received supplement of a 100mg resveratrol tablet (total resveratrol: oligo-stilbene 27.97 mg/100 mg/day) or placebo daily for 12 weeks. CAVI was assessed at baseline and the end of study. Body weight (BW), blood pressure (BP), glucose and lipid metabolic parameters, and diacron-reactive oxygen metabolites (d-ROMs; an oxidative stress marker) were also measured.Resveratrol supplementation decreased systolic BP (-5.5 ± 13.0 mmHg), d-ROMs (-25.6 ± 41.8 U.CARR), and CAVI (-0.4 ± 0.7) significantly (P < 0.05) and decreased BW (-0.8 ± 2.1 kg, P = 0.083) and body mass index (-0.5 ± 0.8 kg/m2, P = 0.092) slightly compared to baseline, while there were no significant changes in the placebo group. Decreases in CAVI and d-ROMs were significantly greater in the resveratrol group than in the placebo group. Multivariate logistic regression analysis identified resveratrol supplementation as an independent predictor for a CAVI decrease of more than 0.5.In conclusion, 12-week resveratrol supplementation may improve arterial stiffness and reduce oxidative stress in patients with T2DM. Resveratrol may be beneficial in preventing the development of atherosclerosis induced by diabetes. However, a large-scale cohort study is required to validate the present findings.